Q-omics provides the consensus-scored PFN1P10 profile across patient tissues and cancer cell-line models. PFN1P10 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PFN1P10 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, PFN1P10 RNA expression shows 5,568 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, STAD, and TGCT as cancer lineages where PFN1P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PFN1P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PFN1P10 survival associations across molecular data types. PFN1P10 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PFN1P10 RNA expression–survival associations across cancer types. High PFN1P10 expression shows unfavorable associations in ACC, STAD, ESCA, READ, GBM and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PFN1P10 RNA expression.
This table summarizes PFN1P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for PFN1P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PFN1P10 shows higher tumor expression in STAD. The STAD box plot shows higher PFN1P10 RNA expression in tumor versus normal tissue (log2 FC = +0.069, t-test p = .032).
This table shows molecular features associated with PFN1P10 in patient tissues and cancer cell lines. In patient samples, PFN1P10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
